Welcome to our dedicated page for Sensei Biotherapeutics news (Ticker: SNSE), a resource for investors and traders seeking the latest updates and insights on Sensei Biotherapeutics stock.
Sensei Biotherapeutics, Inc. (SNSE) is a clinical-stage biotechnology pioneer developing tumor microenvironment-activated immunotherapies. This page aggregates all material news and regulatory disclosures about the company's innovative TMAb™ platform and clinical programs.
Investors and industry observers will find timely updates on clinical trial progress, partnership announcements, financial disclosures, and scientific developments. Our curated collection ensures efficient tracking of key milestones in Sensei's quest to create conditionally active cancer therapies.
The repository includes earnings reports, FDA communications, research collaborations, and peer-reviewed publication highlights. All content is vetted for relevance to SNSE's core focus on overcoming immune suppression in solid tumors through pH-sensitive antibody engineering.
Bookmark this page for structured access to Sensei's evolving pipeline updates and corporate announcements. Regularly refreshed content supports informed decision-making about this innovative player in next-generation immuno-oncology.
Sensei Biotherapeutics (Nasdaq: SNSE) announced a Cooperative Research and Development Agreement with the National Cancer Institute (NCI) to advance the development of SNS-101, a pH-selective VISTA-blocking antibody. This collaboration will focus on preclinical studies to explore SNS-101's mechanisms in combination with new therapies, targeting immune checkpoint resistance.
Sensei plans to submit an IND application for SNS-101 by April 2023, with clinical trials expected to start later in the year, subject to regulatory approval. The collaboration aims to validate the efficacy and safety of SNS-101.
Sensei Biotherapeutics (Nasdaq: SNSE) has entered a clinical supply agreement with Regeneron for its anti-PD1 therapy Libtayo® (cemiplimab) to support a Phase 1/2 trial evaluating SNS-101, a VISTA-blocking antibody. The trial, aimed at solid tumors, will begin in 2023, pending regulatory approval. Sensei plans to submit an Investigational New Drug application by April 2023. This collaboration aims to explore the potential of SNS-101 combined with PD-1 inhibition, leveraging preclinical data suggesting strong anti-tumor activity.
eSensei Biotherapeutics (Nasdaq: SNSE) announces the closure of its Boston research site, resulting in a 40% workforce reduction, aimed at decreasing operating expenses. This strategic move is expected to extend the company's cash runway into the second half of 2025. The IND submission for their lead antibody, SNS-101, is anticipated by April 2023. The company will maintain its Rockville, Maryland facility to support ongoing programs, including SNS-101, designed to target the immune checkpoint VISTA.
Sensei Biotherapeutics (NASDAQ: SNSE) announced that CEO John Celebi will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on December 1, 2022, at 2:00 p.m. ET in New York. The event will focus on the company's innovative therapeutics for cancer, specifically the TMAb™ platform, which aims to activate immune responses in the tumor microenvironment. A webcast of the presentation will be available on their website, with a replay accessible for 90 days post-event.
Sensei Biotherapeutics (Nasdaq: SNSE) has presented promising preclinical data for its antibody candidate SNS-101 at the Society for Immunotherapy of Cancer annual meeting. This highly pH-selective antibody targets VISTA, showing significant anti-tumor effects and favorable pharmacokinetics. Additionally, the company is advancing its SNS-102 program, focusing on VSIG4, with plans for an IND filing for SNS-101 in the first half of 2023. Both programs leverage Sensei’s TMAb™ platform aimed at improving cancer therapies.
Sensei Biotherapeutics (Nasdaq: SNSE) reported third-quarter results for 2022, showing a net loss of $13.4 million, up from $9.7 million a year earlier. The company's cash position was $116.6 million, expected to fund operations into Q1 2025. Sensei highlighted favorable preclinical data for SNS-101, which demonstrated a superior cytokine release profile and advanced anti-tumor effects. Upcoming events include a virtual KOL webinar on November 21 and presentations at the SITC Annual Meeting.
Sensei Biotherapeutics (NASDAQ: SNSE) announced a KOL webinar titled “Lessons from VISTA: New Strategies to Address an Important Immune Checkpoint,” scheduled for November 21, 2022, at 2:15 p.m. ET. Featuring Dr. Robert Schreiber, the webinar will cover VISTA's role in immuno-oncology and present data on SNS-101, a VISTA-blocking antibody designed for the low pH tumor microenvironment. Participants can register online, and a recording will be available afterward. The event will conclude with a Fireside Chat with Dr. Schreiber and a live Q&A session.
Sensei Biotherapeutics, Inc. (NASDAQ: SNSE) will present at the 13th Annual Jefferies Global Healthcare Conference in London on November 17, 2022, at 7:25 a.m. GMT. The presentation, led by CEO John Celebi, will highlight the company's focus on developing innovative immuno-oncology therapeutics, particularly through its TMAb™ platform. The lead candidate, SNS-101, targets the VISTA checkpoint in the tumor microenvironment to enhance T cell activation against tumors. A webcast of the presentation will be available on Sensei’s website for approximately 90 days.
Sensei Biotherapeutics (Nasdaq: SNSE) has announced its participation in the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The company will present two posters highlighting their advancements in immuno-oncology. The first presentation will focus on novel T-cell receptors related to the VSIG4 macrophage receptor, while the second will discuss SNS-101, an antibody that enhances anti-PD-1 sensitivity in tumors. These advancements underscore Sensei's commitment to developing innovative cancer therapeutics using their TMAb and ImmunoPhage platforms.
Sensei Biotherapeutics (NASDAQ: SNSE) presented promising data on SNS-101, a monoclonal antibody targeting the immune checkpoint VISTA, at the Sixth Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference. Preclinical results indicate SNS-101 enhances anti-tumor effects when combined with anti-PD-1 antibodies, achieving five complete responses in a resistant tumor model. The antibody also exhibits a favorable pharmacokinetic profile, reducing the risk of cytokine release syndrome compared to traditional VISTA antibodies. This data may support SNS-101's potential for broad oncological applications.
